Fig. 2: Timeline of publication of pivotal phase III randomized clinical trials of COVID-19 therapies. | Nature Reviews Nephrology

Fig. 2: Timeline of publication of pivotal phase III randomized clinical trials of COVID-19 therapies.

From: Therapeutic advances in COVID-19

Fig. 2

Timeline of publication and key features of pivotal phase III randomized clinical trials of COVID-19 therapies. These trials are categorized into six treatment categories: anti-inflammatory agents, antivirals, renin–angiotensin–aldosterone system (RAAS) modification, antithrombotic agents, convalescent plasma and monoclonal antibody therapies. AC, anticoagulation; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; d, days; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIV, noninvasive ventilation; outpts, outpatients; pts, patients. This timeline reflects published data as of 29 May 2022.

Back to article page